NCT05345002 2026-02-20
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
Clinical Trials
79 trialsNCT04919369 2026-02-13
All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06358677 2026-02-13
FACE
University of Utah
Phase 2 Recruiting
NCT04241276 2026-01-07
STARPAC2
Queen Mary University of London
Phase 2 Active not recruiting
NCT07296445 2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT04113863 2025-12-18
ATRA
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT06439888 2025-12-01
LySATRA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT06731140 2025-11-17
Resilire
Fudan University
Phase 2 Recruiting
NCT07187505 2025-09-23
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
Anhui Medical University
Phase NA Active not recruiting
NCT04305041 2025-08-29
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT05999812 2025-05-25
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT06536413 2025-04-08
ATRA
The Methodist Hospital Research Institute
Phase 1/2 Recruiting
NCT02688140 2025-02-26
TUD-APOLLO-064
Technische Universität Dresden
Phase 3 Completed
NCT04700176 2025-02-25
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
NCT06728631 2025-02-24
Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Active not recruiting
NCT06158412 2025-02-19
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT04282668 2024-12-09
A Study of TAS1440 With ATRA in Subjects With r/r AML
Taiho Oncology, Inc.
Phase 1 Terminated
NCT06646666 2024-11-01
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
Ruijin Hospital
Phase 2 Not yet recruiting
NCT03200847 2024-10-01
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
University of Colorado, Denver
Phase 1/2 Completed
NCT05482451 2024-08-21
Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer
China Medical University Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT05832320 2024-05-10
Optimum Induction Therapy of Low-risk APL
Peking University People's Hospital
Phase NA Recruiting
NCT02942758 2024-05-08
AML-ViVA
University Hospital Regensburg
Phase 2 Terminated
NCT03572387 2024-04-30
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT04793919 2024-04-15
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica
Phase 2 Recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02403778 2023-09-21
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
University of Colorado, Denver
Phase 2 Completed
NCT02842827 2023-07-11
IMG-7289-CTP-101
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase 1/2 Completed
NCT02751255 2023-04-28
DARA/ATRA
Amsterdam UMC, location VUmc
Phase 1/2 Completed
NCT03999684 2023-01-23
A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00551460 2023-01-10
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT05497310 2022-10-26
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
Hospital Universitario Dr. Jose E. Gonzalez
Phase 1/2 Unknown
NCT00866918 2022-10-25
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Children's Oncology Group
Phase 3 Completed
NCT00482833 2022-10-12
APL0406
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3 Completed
NCT05297123 2022-03-28
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
First Affiliated Hospital Xi'an Jiaotong University
Phase 1 Unknown
NCT05175508 2022-01-03
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
The First Affiliated Hospital of Soochow University
Phase 2/3 Unknown
NCT01404949 2021-11-30
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02899169 2021-09-08
APL16
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT05016349 2021-08-23
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.
Kafrelsheikh University
Phase 3 Unknown
NCT01064557 2020-10-14
"AIDA" Protocol (LAP 0493)
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase NA Unknown
NCT01064570 2020-10-14
AIDA 2000 Guidelines
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Unknown
NCT02273102 2020-07-21
TCP-ATRA
University of Miami
Phase 1 Completed
NCT03307148 2020-01-22
STAR_PAC
Barts & The London NHS Trust
Phase 1 Completed
NCT00617409 2019-11-08
To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01987297 2019-08-19
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Shanghai Jiao Tong University School of Medicine
Phase 4 Unknown
NCT02717884 2018-10-18
TRANSATRA
University Hospital Freiburg
Phase 1/2 Unknown
NCT01237808 2018-08-01
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation
University of Ulm
Phase 3 Completed
NCT01276730 2017-12-29
Advanced Cervical Cancer Trial in India
University of Louisville
Phase 2 Completed
NCT00151242 2017-09-20
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
University of Ulm
Phase 2/3 Completed
NCT01820624 2017-04-27
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00151255 2017-04-19
All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
University of Ulm
Phase 3 Completed